Content area
Full text
Novartis ($NVS) has added two more mobile apps to its constellation of digital offerings. This time, cancer patients are the target audience. The Swiss drugmaker rolled out an app to help oncology patients find appropriate clinical trials and an app specifically for patients with neuroendocrine tumors (NET).
The clinical-trials search tool already has some Big Pharma competition. Eli Lilly ($LLY), for one, offers its own version,...




